The association between inhaled long-acting bronchodilators and less in-hospital care in newly-diagnosed COPD patients

Respiratory Medicine

Volumn 108, Issue 1, 2014, Pages 153-161

  Kim, Jinhee ^a   Kim, Kyungjoo ^b   Kim, Yuri ^b   Yoo, Kwang Ha ^c   Lee, Chin Kook ^d   Yoon, Hyoung Kyu ^e   Kim, Young Sam ^f   Park, Young Bum ^g   Lee, Jin Hwa ^h   Oh, Yeon Mok ⁱ   Lee, Sang Do ⁱ   Lee, Sei Won ⁱ  

^a National Evidence Based Healthcare Collaborating Agency   (South Korea)

^b National Strategic Coordinating Center for Clinical Research   (South Korea)

^c Konkuk University School of Medicine   (South Korea)

^d The Catholic University of Korea   (South Korea)

^e The Catholic University of Korea   (South Korea)

^f Yonsei University College of Medicine   (South Korea)

^g Hallym University   (South Korea)

^h Ewha Womans University School of Medicine   (South Korea)

ⁱ University of Ulsan College of Medicine   (South Korea)

Author keywords

Chronic obstructive pulmonary disease; Long acting bronchodilator; Medical cost; Medical utilisation

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CORTICOSTEROID; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LONG ACTING DRUG; MUSCARINIC RECEPTOR BLOCKING AGENT; SHORT ACTING DRUG;

AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMORBIDITY; DATA BASE; DRUG COST; DRUG EFFICACY; DRUG UTILIZATION; FEMALE; HEALTH CARE UTILIZATION; HOSPITAL CARE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAID; PRIORITY JOURNAL;

CHRONIC OBSTRUCTIVE PULMONARY DISEASE; LONG-ACTING BRONCHODILATOR; MEDICAL COST; MEDICAL UTILISATION;

ADMINISTRATION, INHALATION; AGED; ALBUTEROL; BRONCHODILATOR AGENTS; DELAYED-ACTION PREPARATIONS; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERTENSION; LENGTH OF STAY; MALE; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; REPUBLIC OF KOREA; RETROSPECTIVE STUDIES; RISK FACTORS; SCOPOLAMINE DERIVATIVES; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME;

EID: 84893703596     PISSN: 09546111     EISSN: 15323064     Source Type: Journal    
DOI: 10.1016/j.rmed.2013.08.003     Document Type: Article

References (41)

1. D.M. Mannino, and A.S. Buist Global burden of COPD: risk factors, prevalence, and future trends Lancet 370 2007 765 773
2. C.J. Murray, A.D. Lopez, and R. Black et al. Global burden of disease 2005: call for collaborators Lancet 370 2007 109 110
3. C.D. Mathers, and D. Loncar Projections of global mortality and burden of disease from 2002 to 2030 PLoS Med 3 2006 e442
4. S.Y. Lee, S.H. Jee, and J.E. Yun et al. Medical expenditure of national health insurance attributable to smoking among the Korean population J Prev Med Public Health 40 2007 227 232
5. National Heart Lung and Blood Institute Morbidity and Mortality: 2004 chartbook on cardiovascular, lung, and blood diseases 2004 US Department of Health and Human Services Washington DC
6. P.M. Calverley, J.A. Anderson, and B. Celli et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease N Engl J Med 356 2007 775 789
7. D.P. Tashkin, B. Celli, and S. Senn et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease N Engl J Med 359 2008 1543 1554
8. Global Institute for Chronic Obstructive Lung Disease Workshop report: global strategy for diagnosis, management, and prevention of COPD Geneva, Switzerland 2011 Available from: http://www.goldcopd.org
9. T. Haahtela, L.E. Tuomisto, and A. Pietinalho et al. A 10 year asthma programme in Finland: major change for the better Thorax 61 2006 663 670
10. S.J. Lim, H.J. Kim, and C.M. Nam et al. Socioeconomic costs of stroke in Korea: estimated from the Korea national health insurance claims database J Prev Med Public Health 42 2009 251 260
11. Y.H. Lee, S.J. Yoon, E.J. Kim, Y.A. Kim, H.Y. Seo, and I.H. Oh Economic burden of asthma in Korea Allergy Asthma Proc 32 2011 35 40
12. R.G. Barr, J. Bourbeau, C.A. Camargo, and F.S. Ram Inhaled tiotropium for stable chronic obstructive pulmonary disease Cochrane Database Syst Rev 2005 CD002876
13. S. Appleton, P. Poole, B. Smith, A. Veale, T.J. Lasserson, and M.M. Chan Long-acting beta2-agonists for poorly reversible chronic obstructive pulmonary disease Cochrane Database Syst Rev 2006 CD001104
14. D.E. Niewoehner, K. Rice, and C. Cote et al. Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator: a randomized trial Ann Intern Med 143 2005 317 326
15. S.I. Rennard, W. Anderson, and R. ZuWallack et al. Use of a long-acting inhaled beta2-adrenergic agonist, salmeterol xinafoate, in patients with chronic obstructive pulmonary disease Am J Respir Crit Care Med 163 2001 1087 1092
16. G. Boyd, A.H. Morice, J.C. Pounsford, M. Siebert, N. Peslis, and C. Crawford An evaluation of salmeterol in the treatment of chronic obstructive pulmonary disease (COPD) Eur Respir J 10 1997 815 821
17. R. Dahl, L.A. Greefhorst, and D. Nowak et al. Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease Am J Respir Crit Care Med 164 2001 778 784
18. P. Calverley, R. Pauwels, and J. Vestbo et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial Lancet 361 2003 449 456
19. R. Dahl, K.F. Chung, and R. Buhl et al. Efficacy of a new once-daily long-acting inhaled beta2-agonist indacaterol versus twice-daily formoterol in COPD Thorax 65 2010 473 479
20. O. Kornmann, R. Dahl, and S. Centanni et al. Once-daily indacaterol versus twice-daily salmeterol for COPD: a placebo-controlled comparison Eur Respir J 37 2011 273 279
21. K.R. Chapman, S.I. Rennard, A. Dogra, R. Owen, C. Lassen, and B. Kramer Long-term safety and efficacy of indacaterol, a long-acting beta(2)-agonist, in subjects with COPD: a randomized, placebo-controlled study Chest 140 2011 68 75
22. National Institute for Clinical Excellence NICE clinical guideline 101: chronic obstructive pulmonary disease 2012 [cited 2012 November 18]; Available from: www.nice.org.uk/guidance/CG101
23. D.W. Mapel, M. Schum, E. Lydick, and J.P. Marton A new method for examining the cost savings of reducing COPD exacerbations Pharmacoeconomics 28 2010 733 749
24. Morbidity and mortality: 2009 chart book on cardiovascular; lung, and blood diseases 2009 National Institutes of Health, National Heart Lung and Blood Institute (NHLBI) [cited 2012 7 November]; Available from: http://www.nhlbi. nih.gov/resources/docs/2009-ChartBook-508.pdf
25. D.E. Niewoehner The impact of severe exacerbations on quality of life and the clinical course of chronic obstructive pulmonary disease Am J Med 119 2006 38 45
26. S.A. Strassels, D.H. Smith, S.D. Sullivan, and P.S. Mahajan The costs of treating COPD in the United States Chest 119 2001 344 352
27. A.A. Dalal, L. Christensen, F. Liu, and A.A. Riedel Direct costs of chronic obstructive pulmonary disease among managed care patients Int J Chron Obstruct Pulmon Dis 5 2010 341 349
28. M.K. Pasquale, S.X. Sun, F. Song, H.J. Hartnett, and S.A. Stemkowski Impact of exacerbations on health care cost and resource utilization in chronic obstructive pulmonary disease patients with chronic bronchitis from a predominantly medicare population Int J Chron Obstruct Pulmon Dis 7 2012 757 764
29. J.R. Hurst, J. Vestbo, and A. Anzueto et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease N Engl J Med 363 2010 1128 1138
30. J.M. Wells, G.R. Washko, and M.K. Han et al. Pulmonary arterial enlargement and acute exacerbations of COPD N Engl J Med 367 2012 913 921
31. T.A. Lee, A.S. Pickard, D.H. Au, B. Bartle, and K.B. Weiss Risk for death associated with medications for recently diagnosed chronic obstructive pulmonary disease Ann Intern Med 149 2008 380 390
32. F.T. Shaya, D. Dongyi, and M.O. Akazawa et al. Burden of concomitant asthma and COPD in a medicaid population Chest 134 2008 14 19
33. A.V. Gonzalez, S. Suissa, and P. Ernst Gender differences in survival following hospitalisation for COPD Thorax 66 2011 38 42
34. D.S. Kim, Y.S. Kim, and K.S. Jung et al. Prevalence of chronic obstructive pulmonary disease in Korea: a population-based spirometry survey Am J Respir Crit Care Med 172 2005 842 847
35. K.H. Yoo, Y.S. Kim, and S.S. Sheen et al. Prevalence of chronic obstructive pulmonary disease in Korea: the fourth Korean National Health and Nutrition Examination Survey, 2008 Respirology 16 2011 659 665
36. D.C. Suh, H. Lau, S.M. Pokras, I.S. Choi, and E. Valiyeva Sex differences in ambulatory visits for chronic obstructive pulmonary disease, based on the National Ambulatory Medical Care Survey and the National Hospital Ambulatory Medical Care Survey from 1995 to 2004 Respir Care 53 2008 1461 1469
37. R. Endevelt, O. Baron-Epel, A. Viner, and A.D. Heymann Socioeconomic status and gender affects utilization of medical nutrition therapy Diabetes Res Clin Pract 2013 May 20 10.1016/j.diabres.2013.04.011 pii:S0168-8227(13)00167-8. [Epub ahead of print]
38. A. Bostrom, M. von Lehe, and W. Hartmann et al. Surgery for spinal cord ependymomas: outcome and prognostic factors Neurosurgery 68 2011 302 308 [discussion 9]
39. R.J. Adams, A. Fuhlbrigge, T. Guilbert, P. Lozano, and F. Martinez Inadequate use of asthma medication in the United States: results of the asthma in America national population survey J Allergy Clin Immunol 110 2002 58 64
40. C.L. Tsai, and C.A. Camargo Jr. Racial and ethnic differences in emergency care for acute exacerbation of chronic obstructive pulmonary disease Acad Emerg Med 16 2009 108 115
41. D.D. Sin, and S.F. Man Chronic obstructive pulmonary disease: a novel risk factor for cardiovascular disease Can J Physiol Pharmacol 83 2005 8 13